Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 6/20 | 0.43 |
| ▸ | NPY4R | P50391 | 6/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.43 |
| ▸ | NPY1R | P25929 | 4/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844274 | 0.91 | F2 (0.51) | F2OPRM1GRB2NTSR2NTSR1 | |
| SCHEMBL30537473 | 0.90 | NPY2R (0.50) | OPRM1NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30844349 | 0.89 | CALCRL (0.47) | F2OPRM1GRB2CTSDBACE1 | |
| SCHEMBL31676648 | 0.88 | F2 (0.48) | F2OPRM1GRB2NTSR2NTSR1 | |
| SCHEMBL29413017 | 0.88 | F2 (0.56) | F2OPRM1GRB2NTSR2NTSR1 | |
| SCHEMBL29412990 | 0.88 | F2 (0.56) | F2OPRM1GRB2NTSR2NTSR1 | |
| SCHEMBL29844485 | 0.88 | CALCRL (0.48) | F2OPRM1GRB2NPY2RNPY4R | |
| SCHEMBL8838927 | 0.87 | CALCRL (0.46) | F2OPRM1NPY2RNPY4RNPY5R | |
| SCHEMBL8838938 | 0.87 | CALCRL (0.46) | F2OPRM1NPY2RNPY4RNPY5R | |
| SCHEMBL30554067 | 0.87 | F2 (0.50) | F2OPRM1GRB2NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | claimed |
| CN-119317364-A | Novel isolated peptides, protein hydrolysates comprising said isolated peptides and uses thereof | 丰年(大众)有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
| JP-2025518505-A | — | ベタグロ パブリック カンパニー リミテッド | 2025-06-17 | — | — | JP | disclosed |
| CN-119317364-A | Novel isolated peptides, protein hydrolysates comprising said isolated peptides and uses thereof | 丰年(大众)有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023218231-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | VIP, ARGLU1, PELP1 | F2 2838/4885OPRM1 467/4885GRB2 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.